Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, with activities focused on early-stage investments in areas of high unmet patient need, today…
The German Accelerator Life Sciences (GALS) has appointed Stefan B. Beerhalter as Vice President Germany. Mr. Beerhalter has more than 25 years of experience in the medical device industry and held various international and national senior management…
The release of stress hormones triggers a wide variety of different responses in the organism. Some of these responses are controlled by so-called enhancers, regulatory regions in the genome, which influence the activity of genes. Scientists at the…
Instead of defending the body against lymphoma, special immune cells sometimes have the opposite effect. The cancer reprograms the dendritic cells to promote lymphoma tumor growth. Researchers at the Max Delbrück Center for Molecular Medicine in the…
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes responsible for erasing…
The UN Global Compact is the world's largest and most important initiative for responsible corporate governance, involving more than 12,800 companies and organizations from more than 160 countries, 454 of them from Germany. The vision of this United…
The IT specialist for medicine, Professor Sylvia Thun, will be the new Director for eHealth and Interoperability at Berlin Institute of Health (BIH). The physician and qualified engineer is an expert in national and international IT standards in the…
• MOLOGEN to receive a EUR 3 million initial payment as well as a EUR 2 million equity investment • Milestone payments of above EUR 100 million and double digit royalties on net sales • Strong support for global development program of lefitolimod,…
A study conducted by the 3.works institute from Düsseldorf confirms, that KNAUER is one of the companies in Germany with the best employer ratings. The results of the study will be published in cooperation with the renowned ZEIT publishing group.
Research License Agreement on Unique Technology to Assess Drug Effects on the Immune System in Vitro.
